The morning session highlighted a target price cut for Sony Group, along with developments at MONOGATARI CORPORATION, 日本電設工業, オーウイル, MonotaRO and Heartseed. The main points reported were progress in each company’s results and developments related to shareholder returns.
Tokai Tokyo Intelligence Lab changed Sony Group’s target price from ¥4,700 to ¥4,490 while maintaining its “Outperform” rating, citing expectations for collaboration among its entertainment businesses. It was suggested that the launch of GRAND THEFT AUTO 6, a new GOD OF WAR title, strong performance related to Spider-Man, new anime releases and subscriber growth at Crunchyroll are expected to contribute to medium-term profit growth through higher network revenue and the revitalization of intellectual property.
SBI Securities updated its earnings forecasts for MONOGATARI CORPORATION and assessed continued growth in both revenue and operating profit positively. Its target price was changed from ¥5,900 to ¥7,100. The assessment took into account increases in customer traffic and spending per customer at existing stores, strong performance in the yakiniku business and plans to expand the store network.
Tokai Tokyo Intelligence Lab changed its target price for 日本電設工業 from ¥5,200 to ¥4,800, but reaffirmed the company’s steady performance after first-quarter results for the fiscal year ending March 2027 showed revenue up 16% year on year to ¥35.0 billion and operating profit at ¥1.1 billion, marking a return to profitability. The expansion of railway electrical construction work and increased investment by JR East were cited as the background.
SBI Securities’ ownership ratio in オーウイル was reported to have increased from 6.17% to 8.31%, while buying aimed at obtaining shareholder benefits was also expected ahead of the last trading day with entitlement. Daiwa Securities changed its investment rating on MonotaRO to “Outperform” and its target price from ¥2,600 to ¥2,150, while raising its assessment of the stock. The background was said to include progress in the enterprise business.
Heartseed announced that it had obtained a manufacturing and marketing license from the Tokyo Metropolitan Government for regenerative medical products. The company is expected to make progress in establishing a manufacturing and sales system for its allogeneic iPS cell-derived cardiac spheroids currently under development, with a view to future approval applications and a launch in Japan.